GSK plc (NYSE:GSK) Shares Acquired by Pinnacle Financial Partners Inc

Pinnacle Financial Partners Inc grew its position in GSK plc (NYSE:GSKFree Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,732 shares of the pharmaceutical company’s stock after buying an additional 592 shares during the quarter. Pinnacle Financial Partners Inc’s holdings in GSK were worth $435,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of GSK. Royal Bank of Canada grew its stake in GSK by 255.5% during the 2nd quarter. Royal Bank of Canada now owns 7,690,026 shares of the pharmaceutical company’s stock worth $274,071,000 after purchasing an additional 5,526,736 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in GSK by 32.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock worth $419,107,000 after purchasing an additional 2,362,274 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in GSK by 48.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 7,113,039 shares of the pharmaceutical company’s stock worth $309,844,000 after purchasing an additional 2,316,204 shares in the last quarter. Nomura Holdings Inc. acquired a new position in GSK during the 4th quarter worth $73,232,000. Finally, Holocene Advisors LP grew its stake in GSK by 146.7% during the 2nd quarter. Holocene Advisors LP now owns 2,917,836 shares of the pharmaceutical company’s stock worth $103,992,000 after purchasing an additional 1,735,217 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Down 0.6 %

NYSE:GSK opened at $41.55 on Thursday. The stock has a 50-day simple moving average of $41.91 and a 200-day simple moving average of $38.53. The stock has a market cap of $85.52 billion, a P/E ratio of 13.80, a P/E/G ratio of 1.92 and a beta of 0.64. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88.

GSK (NYSE:GSKGet Free Report) last released its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.04). The business had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. As a group, analysts anticipate that GSK plc will post 4.07 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd will be issued a $0.3564 dividend. This is an increase from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend is Thursday, February 22nd. GSK’s payout ratio is presently 52.82%.

Analysts Set New Price Targets

Several research analysts recently commented on GSK shares. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Morgan Stanley began coverage on GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating for the company. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Finally, Jefferies Financial Group raised GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Get Our Latest Report on GSK

GSK Company Profile

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

See Also

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.